CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis.

Target Oncol · 2026 · PMC12924825 · PMID 41559355

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Although overall survival data remain immature, the median OS was not reached in the palbociclib arm compared with 77.0 months in the control arm (thus indicating a favorable trend that requires longer follow-up for confirmation [ 16 ]).

also in 993 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.